Literature DB >> 31160287

In Vitro Activity of Levonadifloxacin (WCK 771) against Chlamydia pneumoniae.

Stephan Kohlhoff1, Natalia Huerta1, Margaret R Hammerschlag2.   

Abstract

Entities:  

Keywords:  Chlamydia pneumoniaezzm321990; levonadifloxacin; quinolones

Mesh：

Substances：

Year:  2019        PMID： 31160287      PMCID： PMC6658800          DOI： 10.1128/AAC.01048-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

1.  Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.

Authors:  M R Hammerschlag; P M Roblin
Journal:  Int J Antimicrob Agents       Date:  2000-07       Impact factor: 5.283

2.  Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.

Authors:  M R Hammerschlag; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  In Vitro Activity of Omadacycline against Chlamydia pneumoniae.

Authors:  Stephan A Kohlhoff; Natalia Huerta; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

4.  Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.

Authors:  P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

5.  Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; Rakesh Chugh; Mugdha Gupta; Ravindra Yeole; Anasuya Patel; Ashima Bhatia
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

6.  Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes.

Authors:  Adnan Al-Lahham; Noel J De Souza; Mahesh Patel; Ralf René Reinert
Journal:  J Antimicrob Chemother       Date:  2005-10-20       Impact factor: 5.790

7.  Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.

Authors:  Blair Capitano; Holly M Mattoes; Eric Shore; Aidan O'Brien; Sidney Braman; Chistina Sutherland; David P Nicolau
Journal:  Chest       Date:  2004-03       Impact factor: 9.410

8.  In Vitro Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms.

Authors:  G Xue; D M Crabb; L Xiao; Y Liu; K B Waites
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191
  8 in total
  2 in total

Review 1.  Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence.

Authors:  Sachin S Bhagwat; Manohar Nandanwar; Atul Kansagara; Anusuya Patel; Swapna Takalkar; Rajesh Chavan; Hariharan Periasamy; Ravindra Yeole; Prasad K Deshpande; Satish Bhavsar; Ashima Bhatia; Jaishid Ahdal; Rishi Jain; Mahesh Patel
Journal:  Drug Des Devel Ther       Date:  2019-12-24       Impact factor: 4.162

2.  Assaying Chlamydia pneumoniae Persistence in Monocyte-Derived Macrophages Identifies Dibenzocyclooctadiene Lignans as Phenotypic Switchers.

Authors:  Eveliina Taavitsainen; Maarit Kortesoja; Tanja Bruun; Niklas G Johansson; Leena Hanski
Journal:  Molecules       Date:  2020-01-11       Impact factor: 4.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.